INM - InMed Pharmaceuticals Inc. Stock Price, Fair Value and News

0.29USD+0.01 (+3.57%)Market Closed

Market Summary

USD0.29+0.01

Market Closed

3.57%

INM Stock Price

View Fullscreen

INM RSI Chart

INM Valuation

Market Cap

2.4M

Price/Earnings (Trailing)

-0.4

Price/Sales (Trailing)

0.43

EV/EBITDA

0.88

Price/Free Cashflow

-0.33

INM Price/Sales (Trailing)

INM Profitability

Operating Margin

45.40%

EBT Margin

-107.98%

Return on Equity

-54.72%

Return on Assets

-45.49%

Free Cashflow Yield

-300.21%

INM Fundamentals

INM Revenue

Revenue (TTM)

5.6M

Rev. Growth (Yr)

13.41%

Rev. Growth (Qtr)

-5.45%

INM Earnings

Earnings (TTM)

-6.1M

Earnings Growth (Yr)

13.77%

Earnings Growth (Qtr)

-16.55%

Breaking Down INM Revenue

Last 7 days

11.5%

Last 30 days

-3.3%

Last 90 days

-14.7%

Trailing 12 Months

-79.1%

How does INM drawdown profile look like?

INM Financial Health

Current Ratio

6.58

INM Investor Care

Shares Dilution (1Y)

151.13%

Diluted EPS (TTM)

0.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.6M	0	0	0
2023	2.3M	4.1M	4.7M	5.5M
2022	0	1.1M	1.4M	1.6M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of InMed Pharmaceuticals Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 21, 2024	hull andrew	bought	14,625	0.39	37,500	-
Feb 20, 2024	adams eric a	bought	14,921	0.3587	41,600	president & ceo
Apr 14, 2022	adams eric a	bought	12,659	0.894	14,160	president & ceo
Apr 13, 2022	adams eric a	bought	7,276	0.85	8,560	president & ceo
Jan 24, 2022	colwill bruce	bought	5,438	1.0877	5,000	cfo
Jan 06, 2022	johnson shane aaron	bought	10,710	1.26	8,500	svp, gm of baymedica llc
Dec 30, 2021	johnson shane aaron	bought	10,736	1.3266	8,093	svp, gm of baymedica llc
Nov 15, 2021	johnson shane aaron	bought	6,845	1.369	5,000	svp, gm of baymedica llc
Sep 29, 2021	adams eric a	bought	15,224	1.73	8,800	president & ceo
Sep 28, 2021	colwill bruce	bought	8,840	1.768	5,000	cfo

Which funds bought or sold INM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-6.00	36.00	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	14.00	14.00	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	added	29.62	11,493	97,176	-%
May 15, 2024	SABBY MANAGEMENT, LLC	reduced	-29.34	-81,296,000	131,669,000	0.08%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	19.61	250	5,614	-%
May 15, 2024	Royal Bank of Canada	added	127	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-62.58	-9,669	4,479	-%
May 14, 2024	TORONTO DOMINION BANK	unchanged	-	-	1.00	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	-13.00	70.00	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-27.25	-6,000	10,000	-%

Are Funds Buying or Selling INM?

Are funds buying INM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INM

No. of Funds

Unveiling InMed Pharmaceuticals Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	606,214	SC 13G/A
Jan 04, 2024	sabby management, llc	9.99%	524,972	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	165,685	SC 13G
Feb 04, 2022	hudson bay capital management lp	3.81%	559,944	SC 13G/A
Feb 09, 2021	hudson bay capital management lp	5.97%	444,444	SC 13G

Recent SEC filings of InMed Pharmaceuticals Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Mar 20, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Feb 27, 2024	3	Insider Trading

Peers (Alternatives to InMed Pharmaceuticals Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

InMed Pharmaceuticals Inc. News

Latest updates

InMed Pharmaceuticals Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-5.5%	1,172,601	1,240,200	901,862	2,311,065	1,033,925	469,783	320,788	525,323	309,585	265,092
Cost Of Revenue	-	883,143	-	-	1,008,520	841,414	338,620	235,034	-	127,308	153,537
Gross Profit	-10.7%	289,458	324,142	21,242	1,570,380	192,511	131,163	-491,018	-	182,277	111,555
Operating Expenses	8.4%	2,133,782	1,969,087	2,694,113	2,048,365	2,341,719	2,345,047	3,084,969	6,769,689	3,721,902	4,423,653
S&GA Expenses	-100.0%	-	1,363,958	1,298,731	1,409,435	1,412,727	1,464,879	1,560,477	1,742,360	1,915,017	1,836,786
R&D Expenses	7.7%	656,764	609,791	1,292,093	623,744	878,303	851,356	1,378,653	1,500,748	1,753,545	2,537,070
EBITDA Margin	-Infinity%	-1.04	-	-1.51	-1.96	-6.65	-10.52	-13.57	-17.23	-	-
Interest Expenses	-	-	-	-	-	-1,500	-3,000	-6,800	-	-	-
Income Taxes	-	-	-	-	1,800	1,500	3,000	6,800	-	-	-
Earnings Before Taxes	-16.6%	-1,722,866	-1,478,185	-2,536,828	-336,591	-1,996,444	-2,098,087	-3,503,400	-7,870,023	-3,475,665	-4,282,814
EBT Margin	6.7%	-1.08	-1.16	-1.48	-1.92	-6.58	-10.43	-13.47	-17.07	-	-
Net Income	-16.6%	-1,722,866	-1,478,185	-2,536,828	-338,391	-1,997,944	-2,101,087	-3,510,200	-7,870,023	-3,475,665	-4,282,814
Net Income Margin	6.7%	-1.08	-1.16	-1.48	-1.92	-6.59	-10.43	-13.47	-17.07	-	-
Free Cashflow	-Infinity%	-1,934,324	-	-2,206,029	-689,750	-1,656,626	-2,713,096	-2,255,543	-4,047,247	-5,352,339	-3,319,363

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Assets	-12.4%	13,359	15,255	10,917	14,106	14,730	16,920	14,584	12,788	15,486	19,384	17,327	9,781	12,345	11,747	6,604	7,803
Current Assets	-14.8%	10,064	11,810	8,295	11,332	11,843	14,018	11,543	9,598	8,747	12,505	15,976	8,378	10,897	10,249	5,117	6,312
Cash Equivalents	-20.3%	7,601	9,535	6,738	8,913	9,604	11,453	9,350	6,177	5,898	11,280	15,344	7,363	9,454	10,021	4,497	5,806
Inventory	60.3%	1,194	745	1,133	1,616	1,330	1,614	1,779	2,491	1,420	989	-	-	-	-	-	-
Net PPE	-7.4%	1,371	1,481	615	723	753	704	802	904	1,003	1,097	305	327	348	374	385	403
Goodwill	-	-	-	-	-	-	-	-	-	2,023	2,023	-	-	-	-	-	-
Liabilities	-9.2%	2,254	2,483	1,339	2,017	2,342	2,585	3,576	3,709	4,599	5,216	2,106	2,405	1,931	4,157	2,110	1,924
Current Liabilities	-9.0%	1,529	1,680	1,339	2,001	2,270	2,401	3,282	3,320	4,106	4,618	1,927	2,215	1,714	2,154	1,874	1,676
Short Term Borrowings	-	-	-	-	-	-	-	-	-	29.00	59.00	-	-	-	-	-	-
Shareholder's Equity	-13.1%	11,105	12,772	9,578	12,090	12,388	14,335	11,008	9,079	10,887	14,167	15,222	7,377	10,414	7,591	4,494	5,878
Retained Earnings	-1.6%	-107,100	-105,400	-103,900	-101,400	-101,061	-99,063	-96,962	-93,452	-85,582	-82,106	-77,824	-74,852	-71,593	-68,492	-66,248	-64,649
Additional Paid-In Capital	-1.6%	37,507	38,122	35,766	35,741	35,701	38,408	35,171	31,684	26,515	27,049	29,230	21,513	21,292	17,946	17,850	17,764
Shares Outstanding	11.9%	6,345	5,668	3,328	3,328	3,328	1,583	866	651	533	554	482	322	322	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-4.7%	-1,934	-1,848	-2,174	-657	-1,656	-2,713	-2,255	-4,047	-5,348	-3,533	-2,653	-2,006	-4,611	-1,801	-1,371	-1,398	-1,521	-2,089	-2,365
Share Based Compensation	202.8%	55.00	18.00	25.00	-	50.00	71.00	117	177	195	215	111	221	207	97.00	85.00	156	204	284	350
Cashflow From Investing	-Infinity%	-2*	-	-	-33.61	-128	-	-	-725	-3.55	306	-250	-	-	-	-	918*	-8.80	55.00	3,744
Cashflow From Financing	-	-	-	-	-	-63.70	5,315	5,429	5,051	-29.31	-836	10,885	-83.18	4,045	6,958	-64.65	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Sales	$ 1,172,601	$ 1,033,925	$ 3,314,663	$ 1,824,496
Cost of sales	883,143	841,414	2,416,417	1,415,068
Inventory write-down			263,404	576,772
Gross profit	289,458	192,511	634,842	(167,344)
Operating Expenses
Research and development and patents	656,764	878,303	2,558,648	3,108,312
General and administrative	1,374,095	1,412,727	4,036,784	4,438,083
Amortization and depreciation	54,767	50,689	164,833	148,786
Foreign exchange loss	48,156	2,733	36,717	79,287
Total operating expenses	2,133,782	2,344,452	6,796,982	7,774,468
Other Income (Expense)
Interest and other income	121,458	155,497	424,261	343,881
Loss before income taxes	(1,722,866)	(1,996,444)	(5,737,879)	(7,597,931)
Tax expense		(1,500)		(11,300)
Net loss for the period	$ (1,722,866)	$ (1,997,944)	$ (5,737,879)	$ (7,609,231)
Net loss per share for the period
Basic (in Dollars per share)	$ (0.18)	$ (0.6)	$ (0.82)	$ (3.53)
Weighted average outstanding common shares
Basic (in Shares)	9,612,973	3,328,191	6,961,938	2,156,283

INM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Current
Cash and cash equivalents	$ 7,600,598	$ 8,912,517
Short-term investments	43,085	44,422
Accounts receivable, net of allowance for credit losses of $66,775 in 2024 and 2023	207,681	260,399
Inventories	1,193,952	1,616,356
Prepaids and other current assets	1,018,686	498,033
Total current assets	10,064,002	11,331,727
Non-Current
Property, equipment and ROU assets, net	1,370,969	723,426
Intangible assets, net	1,823,745	1,946,279
Other assets	100,000	104,908
Total Assets	13,358,716	14,106,340
Current
Accounts payable and accrued liabilities	1,183,285	1,608,735
Current portion of lease obligations	345,545	375,713
Deferred rent		16,171
Total current liabilities	1,528,830	2,000,619
Non-current
Lease obligations, net of current portion	725,236	15,994
Total Liabilities	2,254,066	2,016,613
Commitments and Contingencies (Note 11)
Shareholders’ Equity
Common shares, no par value, unlimited authorized shares, 6,344,970 (June 30, 2023 - 3,328,191) issued and outstanding	80,606,863	77,620,252
Additional paid-in capital	37,507,306	35,741,115
Accumulated deficit	(107,138,088)	(101,400,209)
Accumulated other comprehensive income	128,569	128,569
Total Shareholders’ Equity	11,104,650	12,089,727
Total Liabilities and Shareholders’ Equity	$ 13,358,716	$ 14,106,340

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

CEO	Mr. Eric A. Adams B.S. Chem., M.I.B.
WEBSITE	inmedpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	13

InMed Pharmaceuticals Inc. Frequently Asked Questions

What is the ticker symbol for InMed Pharmaceuticals Inc.? What does INM stand for in stocks?

INM is the stock ticker symbol of InMed Pharmaceuticals Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of InMed Pharmaceuticals Inc. (INM)?

As of Fri May 17 2024, market cap of InMed Pharmaceuticals Inc. is 2.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INM stock?

You can check INM's fair value in chart for subscribers.

What is the fair value of INM stock?

You can check INM's fair value in chart for subscribers. The fair value of InMed Pharmaceuticals Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of InMed Pharmaceuticals Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is InMed Pharmaceuticals Inc. a good stock to buy?

The fair value guage provides a quick view whether INM is over valued or under valued. Whether InMed Pharmaceuticals Inc. is cheap or expensive depends on the assumptions which impact InMed Pharmaceuticals Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INM.

What is InMed Pharmaceuticals Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, INM's PE ratio (Price to Earnings) is -0.4 and Price to Sales (PS) ratio is 0.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INM PE ratio will change depending on the future growth rate expectations of investors.